RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 1.47 Million USD | 5.23% |
| 2021 | 1.4 Million USD | 2.48% |
| 2020 | 1.37 Million USD | 2.44% |
| 2019 | 1.33 Million USD | -3.9% |
| 2018 | 1.39 Million USD | -7.21% |
| 2017 | 1.5 Million USD | -15.05% |
| 2016 | 1.76 Million USD | -0.16% |
| 2015 | 1.77 Million USD | 13.8% |
| 2014 | 1.55 Million USD | 64.82% |
| 2013 | 943.73 Thousand USD | -56.79% |
| 2012 | 2.18 Million USD | -70.97% |
| 2011 | 7.52 Million USD | 27.91% |
| 2010 | 5.88 Million USD | -9.6% |
| 2009 | 6.5 Million USD | -40.61% |
| 2008 | 10.95 Million USD | -9.35% |
| 2007 | 12.08 Million USD | 33.36% |
| 2006 | 9.06 Million USD | 59.84% |
| 2005 | 5.66 Million USD | 69.61% |
| 2004 | 3.34 Million USD | 105.77% |
| 2003 | 1.62 Million USD | 12.4% |
| 2002 | 1.44 Million USD | 191.56% |
| 2001 | 495.69 Thousand USD | 6.96% |
| 2000 | 463.43 Thousand USD | 129.23% |
| 1999 | 202.16 Thousand USD | -65.91% |
| 1998 | 593.09 Thousand USD | -31.83% |
| 1997 | 870.01 Thousand USD | -56.95% |
| 1996 | 2.02 Million USD | -58.01% |
| 1995 | 4.81 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 324.1 Thousand USD | -1.2% |
| 2023 Q2 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 FY | 1.47 Million USD | 5.23% |
| 2022 Q1 | 363.03 Thousand USD | -6.14% |
| 2022 Q2 | 484.03 Thousand USD | 33.33% |
| 2022 Q3 | 303.65 Thousand USD | -37.27% |
| 2022 Q4 | 328.03 Thousand USD | 8.03% |
| 2021 Q2 | 276.63 Thousand USD | -13.17% |
| 2021 Q3 | 423.23 Thousand USD | 52.99% |
| 2021 FY | 1.4 Million USD | 2.48% |
| 2021 Q4 | 386.79 Thousand USD | -8.61% |
| 2021 Q1 | 318.6 Thousand USD | 2.81% |
| 2020 Q4 | 309.89 Thousand USD | 3.42% |
| 2020 FY | 1.37 Million USD | 2.44% |
| 2020 Q1 | 357.33 Thousand USD | 11.75% |
| 2020 Q2 | 404.42 Thousand USD | 13.18% |
| 2020 Q3 | 299.64 Thousand USD | -25.91% |
| 2019 Q3 | 305.68 Thousand USD | -17.64% |
| 2019 Q2 | 371.13 Thousand USD | 8.5% |
| 2019 Q1 | 342.05 Thousand USD | 22.59% |
| 2019 FY | 1.33 Million USD | -3.9% |
| 2019 Q4 | 319.76 Thousand USD | 4.61% |
| 2018 Q2 | 354.61 Thousand USD | -7.39% |
| 2018 Q3 | 376.49 Thousand USD | 6.17% |
| 2018 Q4 | 279.01 Thousand USD | -25.89% |
| 2018 FY | 1.39 Million USD | -7.21% |
| 2018 Q1 | 382.91 Thousand USD | 16.35% |
| 2017 Q4 | 329.1 Thousand USD | -27.84% |
| 2017 Q3 | 456.04 Thousand USD | 44.44% |
| 2017 FY | 1.5 Million USD | -15.05% |
| 2017 Q1 | 400.4 Thousand USD | 11.82% |
| 2017 Q2 | 315.72 Thousand USD | -21.15% |
| 2016 Q3 | 391.28 Thousand USD | -23.33% |
| 2016 Q4 | 358.07 Thousand USD | -8.49% |
| 2016 Q1 | 507.61 Thousand USD | 29.13% |
| 2016 FY | 1.76 Million USD | -0.16% |
| 2016 Q2 | 510.35 Thousand USD | 0.54% |
| 2015 FY | 1.77 Million USD | 13.8% |
| 2015 Q4 | 393.09 Thousand USD | 0.67% |
| 2015 Q1 | 430.97 Thousand USD | 15.82% |
| 2015 Q3 | 390.48 Thousand USD | -29.72% |
| 2015 Q2 | 555.6 Thousand USD | 28.92% |
| 2014 Q1 | 363.55 Thousand USD | 101.12% |
| 2014 Q2 | 406.01 Thousand USD | 11.68% |
| 2014 Q4 | 372.11 Thousand USD | -10.08% |
| 2014 FY | 1.55 Million USD | 64.82% |
| 2014 Q3 | 413.8 Thousand USD | 1.92% |
| 2013 Q3 | 161.63 Thousand USD | -34.42% |
| 2013 Q2 | 246.48 Thousand USD | -30.54% |
| 2013 Q1 | 354.85 Thousand USD | -4.9% |
| 2013 FY | 943.73 Thousand USD | -56.79% |
| 2013 Q4 | 180.76 Thousand USD | 11.83% |
| 2012 Q2 | 767.39 Thousand USD | 17.37% |
| 2012 Q3 | 389.85 Thousand USD | -49.2% |
| 2012 Q4 | 373.12 Thousand USD | -4.29% |
| 2012 FY | 2.18 Million USD | -70.97% |
| 2012 Q1 | 653.8 Thousand USD | -43.3% |
| 2011 Q2 | 2.12 Million USD | -3.57% |
| 2011 FY | 7.52 Million USD | 27.91% |
| 2011 Q4 | 1.15 Million USD | -43.73% |
| 2011 Q3 | 2.04 Million USD | -3.41% |
| 2011 Q1 | 2.19 Million USD | 28.12% |
| 2010 Q1 | 1.14 Million USD | -10.31% |
| 2010 Q2 | 1.38 Million USD | 20.44% |
| 2010 Q3 | 1.63 Million USD | 18.04% |
| 2010 FY | 5.88 Million USD | -9.6% |
| 2010 Q4 | 1.71 Million USD | 5.15% |
| 2009 Q3 | 1.24 Million USD | -15.04% |
| 2009 Q4 | 1.28 Million USD | 3.07% |
| 2009 FY | 6.5 Million USD | -40.61% |
| 2009 Q2 | 1.46 Million USD | -42.0% |
| 2009 Q1 | 2.52 Million USD | -10.04% |
| 2008 Q3 | 2.54 Million USD | -12.5% |
| 2008 Q4 | 2.8 Million USD | 10.32% |
| 2008 FY | 10.95 Million USD | -9.35% |
| 2008 Q2 | 2.9 Million USD | 7.15% |
| 2008 Q1 | 2.7 Million USD | -26.68% |
| 2007 Q2 | 2.73 Million USD | -15.04% |
| 2007 Q4 | 3.69 Million USD | 51.05% |
| 2007 FY | 12.08 Million USD | 33.36% |
| 2007 Q1 | 3.21 Million USD | 62.9% |
| 2007 Q3 | 2.44 Million USD | -10.39% |
| 2006 Q1 | 1.42 Million USD | -37.54% |
| 2006 Q2 | 359.15 Thousand USD | -74.74% |
| 2006 FY | 9.06 Million USD | 59.84% |
| 2006 Q3 | 2.07 Million USD | 478.07% |
| 2006 Q4 | 1.97 Million USD | -4.99% |
| 2005 Q4 | 2.27 Million USD | 56.41% |
| 2005 FY | 5.66 Million USD | 69.61% |
| 2005 Q1 | 925.02 Thousand USD | 11.2% |
| 2005 Q2 | 1.01 Million USD | 9.47% |
| 2005 Q3 | 1.45 Million USD | 43.73% |
| 2004 Q4 | 831.84 Thousand USD | -15.43% |
| 2004 Q2 | 364.4 Thousand USD | -68.66% |
| 2004 Q1 | 1.16 Million USD | 126.94% |
| 2004 FY | 3.34 Million USD | 105.77% |
| 2004 Q3 | 983.61 Thousand USD | 169.92% |
| 2003 Q3 | 390.56 Thousand USD | -9.53% |
| 2003 FY | 1.62 Million USD | 12.4% |
| 2003 Q2 | 431.73 Thousand USD | 48.99% |
| 2003 Q1 | 289.76 Thousand USD | -38.44% |
| 2003 Q4 | 512.42 Thousand USD | 31.2% |
| 2002 Q1 | 136.11 Thousand USD | 17.76% |
| 2002 Q3 | 347.47 Thousand USD | -29.23% |
| 2002 FY | 1.44 Million USD | 191.56% |
| 2002 Q2 | 490.99 Thousand USD | 260.72% |
| 2002 Q4 | 470.68 Thousand USD | 35.46% |
| 2001 Q1 | 141.42 Thousand USD | -17.31% |
| 2001 FY | 495.69 Thousand USD | 6.96% |
| 2001 Q4 | 115.58 Thousand USD | -1.74% |
| 2001 Q3 | 117.63 Thousand USD | -2.83% |
| 2001 Q2 | 121.05 Thousand USD | -14.4% |
| 2000 FY | 463.43 Thousand USD | 129.23% |
| 2000 Q1 | 112.67 Thousand USD | -42.21% |
| 2000 Q2 | 81.44 Thousand USD | -27.71% |
| 2000 Q3 | 98.28 Thousand USD | 20.67% |
| 2000 Q4 | 171.02 Thousand USD | 74.01% |
| 1999 Q1 | 7206.00 USD | 0.0% |
| 1999 Q2 | -389.00 USD | -105.4% |
| 1999 Q3 | -389.00 USD | 0.0% |
| 1999 Q4 | 194.96 Thousand USD | 50218.25% |
| 1999 FY | 202.16 Thousand USD | -65.91% |
| 1998 FY | 593.09 Thousand USD | -31.83% |
| 1997 FY | 870.01 Thousand USD | -56.95% |
| 1996 FY | 2.02 Million USD | -58.01% |
| 1995 FY | 4.81 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10.732% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 70.672% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.996% |
| Nascent Biotech, Inc. | 2.22 Million USD | 33.685% |
| Rebus Holdings, Inc. | 664 Thousand USD | -122.704% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.031% |
| Qrons Inc. | 643.67 Thousand USD | -129.735% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -279.59% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.426% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -255.915% |
| Skye Bioscience, Inc. | 13.54 Million USD | 89.085% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.296% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 69.931% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -465.0% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.273% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 49.292% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 1.541% |
| Mesoblast Limited | 5.9 Million USD | 74.945% |
| Marizyme, Inc. | 19.23 Million USD | 92.314% |
| Genus plc | 147.7 Million USD | 98.999% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 83.156% |
| Pharming Group N.V. | 225.49 Million USD | 99.344% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 27.82% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -10.228% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 82.267% |
| ContraFect Corporation | 56.88 Million USD | 97.401% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 66.458% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 96.079% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 47.005% |
| MultiCell Technologies, Inc. | 567.42 USD | -260509.778% |
| ONE Bio Corp. | 6.44 Million USD | 77.052% |
| Accustem Sciences Inc. | 3.74 Million USD | 60.529% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.279% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -177.981% |
| Q BioMed Inc. | 3.43 Million USD | 56.971% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.017% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 43.721% |
| Biomind Labs Inc. | 994.18 Thousand USD | -48.741% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.511% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 15.965% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 77.988% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 20.684% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6015.008% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 90.764% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 19.418% |
| GB Sciences, Inc. | 1.42 Million USD | -4.1% |
| Alpha Cognition Inc. | 9.7 Million USD | 84.764% |
| HST Global, Inc. | 140.9 Thousand USD | -949.452% |
| CSL Limited | 3.44 Billion USD | 99.957% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -31.455% |
| Halberd Corporation | 74.84 Thousand USD | -1875.832% |
| Enzolytics Inc. | 2.17 Million USD | 32.152% |
| Agentix Corp. | 1.37 Million USD | -7.8% |
| Resverlogix Corp. | 12.71 Million USD | 88.367% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 59.494% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.904% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -41.643% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 38.512% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 6.37% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 56.571% |
| AVAX Technologies, Inc. | 7.31 Million USD | 79.772% |
| Zenith Capital Corp. | 8.94 Million USD | 83.465% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.821% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8388.33% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 39.773% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -762.201% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 23.018% |
| Kadimastem Ltd | 2.41 Million USD | 38.644% |
| Helix BioMedix, Inc. | 1.97 Million USD | 25.014% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 86.392% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.564% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -714.807% |
| LadRx Corporation | 3.81 Million USD | 61.206% |
| Cell Source, Inc. | 4.32 Million USD | 65.812% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -60.123% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -60.123% |
| NovAccess Global Inc. | 2.46 Million USD | 40.053% |
| Affymax, Inc. | 39.38 Million USD | 96.245% |
| Itoco Inc. | 919.14 Thousand USD | -60.884% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 65.111% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -32.149% |
| Mobile Lads Corp. | 554.54 Thousand USD | -166.66% |
| CytoDyn Inc. | 18.05 Million USD | 91.811% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5775.291% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -571.922% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -4.153% |
| SYBLEU INC | 160.87 Thousand USD | -819.187% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 18.585% |
| International Stem Cell Corporation | 5.27 Million USD | 71.946% |
| Bioxytran, Inc. | 3.82 Million USD | 61.291% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2709.073% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7169.095% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.922% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 8.606% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -100.962% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 52.467% |
| Neutra Corp. | 243.82 Thousand USD | -506.491% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 91.529% |
| PureTech Health plc | 144.59 Million USD | 98.977% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 92.783% |
| IXICO plc | 4.7 Million USD | 68.584% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 83.19% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.744% |
| CSL Limited | 3.89 Billion USD | 99.962% |
| Cellectis S.A. | 97.32 Million USD | 98.481% |